Is Doubling of Serum Creatinine a Valid Clinical ‘Hard’ Endpoint in Clinical Nephrology Trials?
Open Access
- 11 August 2011
- journal article
- review article
- Published by S. Karger AG in Nephron Clinical Practice
- Vol. 119 (3), c195-c199
- https://doi.org/10.1159/000327614
Abstract
The composite of end stage renal disease (ESRD), doubling of serum creatinine and (renal) death, is a frequently used endpoint in randomized clinical trials in nephrology. Doubling of serum creatinine is a well-accepted part of this endpoint because a doubling of serum creatinine reflects a large sustained change in glomerular filtration rate (GFR) and predicts the development of ESRD. Although doubling of serum creatinine is frequently used, the validity of using this outcome as part of a composite endpoint is hampered by various factors. Firstly, serum creatinine may reflect changes in muscle mass unrelated to true GFR changes. Secondly, changes in serum creatinine may reflect hemodynamic changes in renal perfusion and not a structural effect on renal function. Finally, doubling of serum creatinine is an arbitrary choice and different proportional changes may represent a better indicator for ESRD. In this minireview, each of these factors will be discussed and recommendations are made for interpretation of clinical trials using doubling of serum creatinine as a composite endpoint in nephrology trials.This publication has 11 references indexed in Scilit:
- Reversible Effects of Diuretics Added to Renin-Angiotensin-Aldosterone System Blockade: Impact on Interpretation of Long-term Kidney Function OutcomeAmerican Journal of Kidney Diseases, 2010
- Variability of Creatinine Measurements in Clinical Laboratories: Results from the CRIC StudyAmerican Journal of Nephrology, 2010
- Effects of Dietary Sodium and Hydrochlorothiazide on the Antiproteinuric Efficacy of LosartanJournal of the American Society of Nephrology, 2008
- Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathyDiabetic Medicine, 2007
- Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration RateAnnals of Internal Medicine, 2006
- The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros StudyNephrology Dialysis Transplantation, 2001
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesThe New England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyThe New England Journal of Medicine, 2001
- The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic NephropathyThe New England Journal of Medicine, 1993
- Factors influencing the production of creatinine: Implications for the determination and interpretation of urinary creatinine and creatine in manClinica Chimica Acta; International Journal of Clinical Chemistry, 1988